Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871026 | 0.77 | GRIN2B (0.63) | LCKGRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL10154348 | 0.76 | LCK (0.54) | LCKGRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL738354 | 0.76 | LCK (0.54) | LCKGRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL13208750 | 0.75 | SMN1; SMN2 (0.54) | LCKGRIN2BCYP2D6CYP2C9JAK2 | |
| SCHEMBL2499417 | 0.75 | SMN1; SMN2 (0.56) | LCKGRIN2BCYP2D6CYP2C9USP30 | |
| SCHEMBL5364657 | 0.74 | GRIN2B (0.64) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL934391 | 0.74 | KCNH2 (0.38) | — | |
| SCHEMBL5354187 | 0.74 | GRIN2B (0.87) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL3272711 | 0.74 | SMN1; SMN2 (0.58) | LCKGRIN2BCYP2D6CYP2C9JAK2 | |
| SCHEMBL1320424 | 0.74 | SMN1; SMN2 (0.58) | LCKGRIN2BCYP2D6CYP2C9JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | LCK 205/4885GRIN2B 2828/4885CYP2D6 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.